A product launch in the Parkinson’s market – especially when MAO-B inhibitors are involved – is one of the biggest challenges in pharmaceutical marketing.
- Lundbeck GmbH
- Press contact
- Rike Funke
Successful communication concepts in the past for the leading dopamine agonists pramiprexole and cabergoline were able to proactively prevent possible concerns for and a negative image transfer to the new substance.
Based on the present international design and communication guidelines, BRAND HEALTH uses its comprehensive local market knowledge to emotionally imbue the product with new ideas. Transferring the interests of the co-promotion partners into a holistic concept is a matter of course.